Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study published in The Lancet Microbe has found that the transfer of antibiotic resistance genes between different bacteria is considerably more widespread than previously thought.

Hand with gloves showing a sort of antibiotics and a laboratory plate with fungi © TopMicrobialStock, Getty Images.

Researchers at the Ineos Oxford Institute for antimicrobial research (IOI) at Oxford University and Fujian Agriculture and Forestry University in China have developed a new approach, called culture-independent conjugation, to study the transmission of plasmids between bacteria sampled from hospital wastewater.

Plasmids are small circular pieces of DNA that move between neighbouring bacteria (the ‘donor’ bacteria giving the plasmid and the ‘recipient’ bacteria receiving the plasmid) in a process called conjugation. Plasmids containing antibiotic resistance genes are a major driver of antimicrobial resistance (AMR), including resistance against carbapenem- a ‘last-resort’ antibiotic. Carbapenem-resistant bacteria are thought to cause between 50 000 and 100 000 deaths worldwide each year

Up until now, conjugation has been mainly measured with pure cultures containing only one species of bacteria. This has limited understanding of how AMR spreads in bacterial communities in humans, animals, and the environment.

 

Read the full story on the University of Oxford website.

Similar stories

Forecasting how best to control and eliminate Neglected Tropical Diseases

Neglected tropical diseases (NTDs) are a major cause of death, disability, and economic hardship worldwide, particularly in low- and middle-income countries. While many of these diseases are targeted for control, elimination, or eradication by 2030, achieving those targets will be challenging due to disruptions to programmes related to the COVID-19 pandemic and differences in disease transmission across regions, which requires tailoring interventions to local settings.